Galapagos (NASDAQ:GLPG) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Galapagos (NASDAQ:GLPG) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Galapagos Trading Up 0.4%

Shares of NASDAQ:GLPG opened at $32.79 on Friday. Galapagos has a 1 year low of $22.36 and a 1 year high of $33.86. The business has a fifty day simple moving average of $29.23 and a 200 day simple moving average of $26.57.

Institutional Trading of Galapagos

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in shares of Galapagos by 45.9% during the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 2,824 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Galapagos by 354.5% during the first quarter. GAMMA Investing LLC now owns 10,148 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 7,915 shares in the last quarter. Gilead Sciences Inc. purchased a new stake in shares of Galapagos during the fourth quarter worth $461,727,000. American Century Companies Inc. raised its holdings in shares of Galapagos by 5.9% during the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 1,431 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Galapagos by 19.6% during the fourth quarter. Bank of America Corp DE now owns 22,454 shares of the biotechnology company’s stock worth $617,000 after acquiring an additional 3,684 shares in the last quarter. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.